SEC Form SC 13G/A filed by Provention Bio Inc. (Amendment)

2/14/23 4:08:18 PM ET

$PRVB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRVB alert in real time by email

SC 13G/A 1 tm236584d6_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Provention Bio, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

74374N102

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 74374N102

Page 2 of 17


1.	Name of reporting persons Venrock Healthcare Capital Partners II, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹(b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) PN

Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 3 of 17


1.	Name of reporting persons VHCP Co-Investment Holdings II, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) OO

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 4 of 17


1.	Name of reporting persons Venrock Healthcare Capital Partners III, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) PN

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 5 of 17


1.	Name of reporting persons VHCP Co-Investment Holdings III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) OO

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 6 of 17


1.	Name of reporting persons Venrock Healthcare Capital Partners EG, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) PN

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 7 of 17


1.	Name of reporting persons VHCP Management II, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) OO

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 8 of 17


1.	Name of reporting persons VHCP Management III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) OO

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 9 of 17


1.	Name of reporting persons VHCP Management EG, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) OO

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 10 of 17


1.	Name of Reporting Persons Shah, Nimish
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) IN

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 11 of 17


1.	Name of Reporting Persons Koh, Bong
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x¹ (b) ¨
3.	SEC USE ONLY
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With:		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,118,653²
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,118,653²
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,118,653²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 1.3%³
12.	Type of Reporting Person (See Instructions) IN

3	This percentage is calculated based upon 87,190,667 shares of the Issuer’s Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

CUSIP No. 74374N102

Page 12 of 17

Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Provention Bio, Inc.

Item 1.

(a)

Name of Issuer

Provention Bio, Inc.

(b)

Address of Issuer’s Principal Executive Offices

55 Broad Street, 2^nd Floor

Red Bank, New Jersey 07701

Item 2.

(a)

Name of Person Filing

Venrock Healthcare Capital Partners II, L.P.

VHCP Co-Investment Holdings II, LLC

Venrock Healthcare Capital Partners III, L.P.

VHCP Co-Investment Holdings III, LLC

Venrock Healthcare Capital Partners EG, L.P.

VHCP Management II, LLC

VHCP Management III, LLC

VHCP Management EG, LLC

Nimish Shah

Bong Koh

(b)

Address of Principal Business Office or, if none, Residence

	New York Office:	Palo Alto Office:

	7 Bryant Park	3340 Hillview Avenue
	23rd Floor	Palo Alto, CA 94304
	New York, NY 10018

(c)

Citizenship

All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

(d)

Title of Class of Securities

Common Stock, par value $0.0001 per share

CUSIP No. 74374N102

Page 13 of 17

(e)

CUSIP Number

74374N102

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4.

Ownership

(a)

Amount Beneficially Owned as of December 31, 2022:

Venrock Healthcare Capital Partners II, L.P.	1,118,653	(1)
VHCP Co-Investment Holdings II, LLC	1,118,653	(1)
Venrock Healthcare Capital Partners III, L.P.	1,118,653	(1)
VHCP Co-Investment Holdings III, LLC	1,118,653	(1)
Venrock Healthcare Capital Partners EG, L.P.	1,118,653	(1)
VHCP Management II, LLC	1,118,653	(1)
VHCP Management III, LLC	1,118,653	(1)
VHCP Management EG, LLC	1,118,653	(1)
Nimish Shah	1,118,653	(1)
Bong Koh	1,118,653	(1)

(b)

Percent of Class as of December 31, 2022:

Venrock Healthcare Capital Partners II, L.P.	1.3	%
VHCP Co-Investment Holdings II, LLC	1.3	%
Venrock Healthcare Capital Partners III, L.P.	1.3	%
VHCP Co-Investment Holdings III, LLC	1.3	%
Venrock Healthcare Capital Partners EG, L.P.	1.3	%
VHCP Management II, LLC	1.3	%
VHCP Management III, LLC	1.3	%
VHCP Management EG, LLC	1.3	%
Nimish Shah	1.3	%
Bong Koh	1.3	%

(c)

Number of shares as to which the person has, as of December 31, 2022:

(i)

Sole power to vote or to direct the vote

Venrock Healthcare Capital Partners II, L.P.		0
VHCP Co-Investment Holdings II, LLC		0
Venrock Healthcare Capital Partners III, L.P.		0
VHCP Co-Investment Holdings III, LLC		0
Venrock Healthcare Capital Partners EG, L.P.		0
VHCP Management II, LLC		0
VHCP Management III, LLC		0
VHCP Management EG, LLC		0
Nimish Shah		0
Bong Koh		0

CUSIP No. 74374N102

Page 14 of 17

(ii)

Shared power to vote or to direct the vote

Venrock Healthcare Capital Partners II, L.P.	1,118,653	(1)
VHCP Co-Investment Holdings II, LLC	1,118,653	(1)
Venrock Healthcare Capital Partners III, L.P.	1,118,653	(1)
VHCP Co-Investment Holdings III, LLC	1,118,653	(1)
Venrock Healthcare Capital Partners EG, L.P.	1,118,653	(1)
VHCP Management II, LLC	1,118,653	(1)
VHCP Management III, LLC	1,118,653	(1)
VHCP Management EG, LLC	1,118,653	(1)
Nimish Shah	1,118,653	(1)
Bong Koh	1,118,653	(1)

(iii)

Sole power to dispose or to direct the disposition of

Venrock Healthcare Capital Partners II, L.P.		0
VHCP Co-Investment Holdings II, LLC		0
Venrock Healthcare Capital Partners III, L.P.		0
VHCP Co-Investment Holdings III, LLC		0
Venrock Healthcare Capital Partners EG, L.P.		0
VHCP Management II, LLC		0
VHCP Management III, LLC		0
VHCP Management EG, LLC		0
Nimish Shah		0
Bong Koh		0

(iv)

Shared power to dispose or to direct the disposition of

Venrock Healthcare Capital Partners II, L.P.	1,118,653	(1)
VHCP Co-Investment Holdings II, LLC	1,118,653	(1)
Venrock Healthcare Capital Partners III, L.P.	1,118,653	(1)
VHCP Co-Investment Holdings III, LLC	1,118,653	(1)
Venrock Healthcare Capital Partners EG, L.P.	1,118,653	(1)
VHCP Management II, LLC	1,118,653	(1)
VHCP Management III, LLC	1,118,653	(1)
VHCP Management EG, LLC	1,118,653	(1)
Nimish Shah	1,118,653	(1)
Bong Koh	1,118,653	(1)

(1)

Consists of (i) 180,439 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 73,159 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 390,186 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 39,041 shares held by VHCP Co-Investment Holdings III, LLC and (v) 435,828 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC.

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

CUSIP No. 74374N102

Page 15 of 17

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group

Not Applicable

Item 9.

Notice of Dissolution of a Group

Not Applicable

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP No. 74374N102

Page 16 of 17

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

Venrock Healthcare Capital Partners II, L.P.		Venrock Healthcare Capital Partners III, L.P.

By:	VHCP Management II, LLC	By:	VHCP Management III, LLC
Its:	General Partner	Its:	General Partner

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

VHCP Co-Investment Holdings II, LLC		VHCP Co-Investment Holdings III, LLC

By:	VHCP Management II, LLC	By:	VHCP Management III, LLC
Its:	Manager	Its:	Manager

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

VHCP Management II, LLC			VHCP Management III, LLC

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

Venrock Healthcare Capital Partners EG, L.P.		VHCP Management EG, LLC

By:	VHCP Management EG, LLC	/s/ David L. Stepp
Its:	General Partner	Name:	David L. Stepp
		Its:	Authorized Signatory

/s/ David L. Stepp
Name:	David L. Stepp
Its:	Authorized Signatory

Bong Koh

/s/ David L. Stepp
David L. Stepp, Attorney-in-fact

Nimish Shah

/s/ David L. Stepp
David L. Stepp, Attorney-in-fact

CUSIP No. 74374N102

Page 17 of 17

EXHIBITS

A:	Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed with the Securities and Exchange Commission on June 7, 2021)

B:	Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to the Schedule 13G filed with the Securities and Exchange Commission on June 7, 2021)

C:	Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to the Schedule 13G filed with the Securities and Exchange Commission on June 7, 2021)

Get the next $PRVB alert in real time by email

Date	Price Target	Rating	Analyst
9/20/2022	$10.00	Buy	Jefferies
11/23/2021		Neutral → Outperform	SMBC Nikko
8/6/2021	$18.00 → $16.00	Outperform	Oppenheimer
8/6/2021	$27.00 → $25.00	Buy	HC Wainwright & Co.

SEC Form SC 13G/A filed by Provention Bio Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$PRVB

$PRVB
SEC Filings

SEC Form 15-12G filed by Provention Bio Inc.

SEC Form EFFECT filed by Provention Bio Inc.

SEC Form EFFECT filed by Provention Bio Inc.

$PRVB
Financials

Live finance-specific insights

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D

$PRVB
Leadership Updates

Live Leadership Updates

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development

$PRVB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Sessa Capital (Master), L.P.

SEC Form 4 filed by Wysenski Nancy

SEC Form 4 filed by Pisano Wayne

$PRVB
Press Releases

Fastest customizable press release news feed in the world

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

Provention Bio Announces the Grant of Inducement Awards

$PRVB
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$PRVB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

FDA Approval for TZIELD issued to PROVENTION BIO INC